GlassScriptPhysician profile
Jeanine S Hess
NPI 1720581366
$1,019.24
in general payments reported to CMS, 2019-2025
20 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.30 · 2023: $205 · 2024: $407 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160.45 | 2023-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $143.23 | 2023-2025 | Airsupra, Farxiga |
| Sk Life Science, INC. | $82.88 | 2025 | |
| Abbvie INC. | $78.24 | 2022-2024 | |
| Exact Sciences Corporation | $68.26 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $56.41 | 2024-2025 | |
| Lundbeck LLC | $55.49 | 2025 | Rexulti |
| Ucb, INC. | $52.20 | 2023-2025 | Nayzilam, Briviact |
| Neurocrine Biosciences, INC. | $51.00 | 2023-2024 | Ingrezza |
| Amgen INC. | $36.07 | 2023-2024 | Otezla, Repatha, Evenity |
| Pfizer INC. | $34.68 | 2023-2024 | |
| Neurelis, INC. | $33.36 | 2025 | Valtoco |
| Glaxosmithkline, LLC. | $28.11 | 2024 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $27.69 | 2025 | Myfembree |
| Merck Sharp & Dohme LLC | $23.14 | 2024 | Gardasil, M-M-R II, Gardasil 9 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $19.12 | 2025 | Radicava |
| Lilly USA, LLC | $18.12 | 2024 | Mounjaro |
| Exeltis, USA INC. | $17.59 | 2025 | Slynd |
| Genentech USA, INC. | $16.84 | 2025 | Ocrevus |
| Emd Serono, INC. | $16.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanine Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.